EAC 2025 - Update in Allergy, Asthma & Immunology

Palm Beach, FL US
May 29, 2025 to June 1, 2025

The 2025 EAC activity will provide conference attendees with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology.  

In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases.  By means of active discussion, learners will be challenged to formulate and justify medical decision making concerning diagnostic and treatment strategies for patients.  

Topics of discussion will include severe asthma, Chronic urticaria, Atopic dermatitis, Contact dermatitis, Patch testing, CRSwNP and AERD, Biologics for allergic disease, Immunodeficiency, Anaphylaxis, Allergen immunotherapy, Food allergy, Alpha-gal allergy, IgG4 in allergic disease, EoE and EGIDs, Stinging insect hypersensitivity, and HAE.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Allergy Conference (EAC).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 17.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 17.25 contact hours.

This activity is supported in part by an independent medical education grant from BioCryst and in-kind support of disposable materails from SmartPractice.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this activity, participants should be able to:
• Phenotype and treat severe and difficult-to-control asthma in accordance with the most updated guideline-based approach
• Discuss current allergen immunotherapy treatment guidelines for respiratory allergies
• Outline an approach to the use of biologics for allergic diseases, including asthma, CRSwNP, atopic dermatitis and food allergy
• Employ appropriate diagnostic testing, including genetic testing, for the evaluation of potential immunodeficiency 
• Incorporate decision-making into clinical practice
• Diagnose and manage CRSwNP and AERD
• Educate patients regarding epinephrine devices for the management of anaphylaxis
• Diagnose and manage stinging insect hypersensitivity
• Diagnose and manage alpha-gal allergy
• Describe the differences in the prevalence and management of food allergy in each stage of life
• Educate patients regarding treatment options for antihistamine-resistant chronic urticaria
• Perform appropriate allergy diagnostic testing for EoE and EGIDS
• Discuss treatment options for moderate/severe atopic dermatitis
• Diagnose and manage hereditary angioedema
• Utilize patch testing for the diagnosis of contact dermatitis

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 17.25 AMA PRA Category 1 Credit™
  • 17.25 Attendance
  • 17.25 CBRN
Course opens: 
05/29/2025
Course expires: 
12/31/2025
Event starts: 
05/29/2025 - 3:30pm CDT
Event ends: 
06/01/2025 - 11:30am CDT
Add to calendar: 
Rating: 
0

EAC 2025 - Update in Allergy, Asthma & Immunology
Thursday, May 29 - Sunday, June 1 2025
All educational sessions held in Ponce 4

Moderator: Russell Settipane, MD

3:30- 4:00 Alpha-gal allergy update, Thomas Platts-Mills, MD

4:00-4:30 Update in stinging insect hypersensitivity, David Golden, MD

4:30-5:00 AIT update, David Bernstein, MD

5:00- 5:15  Panel Discussion: Q & A

5:15 - 5:45 Vaccines and biologics, Nicole Chase, MD

5:45 - 6:15 Epinephrine: Alternative routes of administration, David Golden, MD

6:15 -6:30 Panel Discussion: Q & A

Friday, May 30, 2025
All educational sessions held in Ponce 4

Moderator: William Greisner III, MD

7:45 - 8:15 Food allergy prevalence, severity, and disparities, Ruchi Gupta, MD

8:15 - 8:45 What you need to know about BTK inhibitors in the treatment of allergic diseases, Melanie Dispenza, MD

8:45 - 8:55 Panel Discussion: Q & A 

8:55 - 10:00 PBL: Chronic urticaria, Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD, Nicole Chase, MD and Dana Wallace, MD

10:00 - 10:45 Coffee Break: Visit exhibits (Ponce 5 & 6) and posters (Ponce foyer) 

10:45 - 11:10 CSU treatment options when omalizumab fails, David Lang, MD

11:10 - 11:20 Panel Discussion: Q & A

11:20 - 11:45 Defining the role of the allergist in EOE management, Emily McGowan, MD

11:45 - 12:15 Role of lgG4 antibodies in allergic diseases, Thomas Platts-Mills, MD

12:15 - 12:25 Panel Discussion: Q & A

Moderator: Robert Settipane, MD

1:20 - 1:45 How to interpret genetic testing in IEI patients: When and what to order, Manish Butte, MD

1:45 - 2:15 Is it time for the allergist-immunologist to embrace AI in the diagnosis and treatment of IEis?, Joseph Bellanti, MD

2:15 -2:25 Panel Discussion: Q & A 

2:25 -2:55 Music therapy in rare diseases, Raffi Tachdjian, MD

2:55 - 3:00 Panel Discussion: Q & A 

Saturday, May 31, 2025
All educational sessions held in Ponce 4

Moderator: Russell Settipane, MD

7:45 - 8:15 Clinical variability in primary immune regulatory disorders, Manish Butte, MD

8:15 - 8:45 What to do when your severe asthma patient does not respond to biologics, Dennis Ledford, MD

8:45 - 8:55 Panel Discussion: Q & A 

8:55 - 10:00 PBL: Atopic dermatitis,Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD, Ellen Sher, MD and Dana Wallace, MD

10:00 - 10:45 Coffee Break: Visit exhibits (Ponce 5 & 6) and posters (Ponce foyer) 

10:45 - 11:15 Treatment update for moderate/severe atopic dermatitis, Dana Wallace, MD

11:15 - 11:45 Adult atopic dermatitis: To patch or not to patch? This is the question, Jenny Murase, MD

11:45 - 11:55 Panel Discussion: Q & A

11:55 - 12:20 The medical management of CRS, NP & AERD in the biologic age, Kathleen Buchheit, MD

12:20- 12:25 Panel Discussion: Q & A

Moderator: Sandra Gawchik, DO

1:20 - 2:20 Asthma phenotype debate
  Juan Carlos Cardet, MD - Asthma phenotyping should be done on all asthma patients
  Dennis Ledford, MD - Asthma phenotyping should be only done on severe asthma patients

2:20 - 2:30 Panel Discussion: Q & A 

2:30-3:30 Patch test workshop, Jenny Murase, MD and Ellen Sher, MD 

Sunday, June l, 2025
All educational sessions held in Ponce 4

Moderator: William Corrao, MD

8:15 - 8:45 Tales of the rash whisper: Untangling the mystery of adult recalcitrant eczematous dermatitis, Jenny Murase, MD

8:45 -9:15 HAE update, Raffi Tachdjian, MD

9:15 -9:20 Panel Discussion: Q & A

10:15 - 10:45  Managing food allergies in each stage of life, Ruchi Gupta, MD

10:45 - 11:15 EGIDs update, Emily McGowan, MD

11:15 - 11:30 Panel Discussion: Q & A

The Breakers
1 South County Road
Palm Beach, FL 33480
United States

All identified relevant financial relationships with ineligible companies have been mitigated.

David Bernstein, MD - Speaker 
Advisor- Aquestive, ARS, Bryn 
Consultant- GSK
Researcher- ARS, GSK

Kathleen Buchheit, MD - Speaker
Advisor- AstraZeneca, Eli Lilly, GSK, Regeneron, Sanofi
Consultant- Sanofi
Researcher- Regeneron 
Royalties- UpToDate

Don Bukstein, MD - Speaker
Advisor- Amphastar 
Speaker- Regeneron, Sanofi

Manish Butte, MD - Speaker 
Advisor- ADMA, Grifols
Consultant- Pharming
Researcher- Pharming
Speaker- Grifols

Juan Carlos Cardet, MD - Speaker
Advisor- Amgen, Apogee, AstraZeneca, Chiesi, Genentech, GSK, Sanofi

Nicole Chase, MD - Speaker
Advisor-Amgen, Apogee, ARS Pharma, AstraZeneca, Blueprint Medicines, BRYN, Cogent, Freed, Genentech, GSK, Incyte, Kenota Health, Novartis, Regeneron, Sanofi
Consultant- ARS Pharma, AstraZeneca, Incyte, Sanofi, Regeneron
Speaker- Amgen, ARS Pharma, AstraZeneca, Blueprint Medicines, Genentech, llluminate Health, Incyte, MJH, Regeneron, Sanofi
Researcher- AstraZeneca, Kenota Health

Ray Davis, MD - Speaker
Consultant- AstraZeneca, Grifols, Kalvista, Regeneron, Sanofi
 
Melanie Dispenza, MD - Speaker 
Consultant- Blueprint Medicines 
Researcher- AstraZeneca

David Golden, MD - Speaker
Consultant- Aquestive, Blueprint, Celldex, Kokua, Novartis 
Speaker- ARS, Thermof isher
Royalties- UpToDate

William Greisner, III, MD- Planner, Moderator
Independent Contractor- Allakos, AstraZeneca, GSK, Regeneron

Ruchi Gupta, MD - Speaker
Consultant- Aquestive Therapeutics, Bryn Pharma, Genentech, Kaleo, Novartis, OWYN 
Researcher- Genentech, Novartis
Ownership Interest- Yobee Care Inc

David Lang, MD - Speaker
Consultant- Celldex, Genentech, Novartis, Regeneron, Sanofi 
Speaker- Regeneron, Sanofi

Dennis Ledford, MD - Speaker
Advisor-AstraZeneca
Speaker-AstraZeneca, Regeneron, Sanofi

Jenny Murase, MD - Speaker
Consultant-AbbVie, Regeneron, Sanofi, UCB, UpToDate 
Speaker- AbbVie, Galderma, Regeneron, Sanofi, UCB

Russell Settipane, MD - Planner/Moderator/Speaker/Reviewer
Advisor- AbbVie, AstraZeneca, BioCryst, DBV, GSK, Kalvista, Pharming, Pfizer
Independent Contractor- AstraZeneca, BioCryst, DBV, Genentech, GSK, Regeneron, Takeda
Speaker- AbbVie, Amgen, AstraZeneca, BioCryst, Genentech, GSK, Grifols, Pharming, Regeneron, Sanofi, Takeda

Ellen Sher, MD-Speaker
Advisor- AstraZeneca, Eli Lily, Genentech, Novartis, Regeneron, Sanofi
Consultant- AstraZeneca, Novartis
Researcher- AstraZeneca, Celldex, Eli Lilly, Genentech, Nocion, Novartis, Regeneron, Sanofi 
Speaker- AbbVie, ARS AstraZeneca, Genentech, GSK, lncyte, Regeneron, Sanofi

Raffi Tachdjian, MD - Speaker
Advisor -Astria, BioCryst, CSL Behring, lonis, Kalvista, Pharming, Pharvaris, Takeda
Independent Contractor- Astria, BioCryst, CSL Behring, lonis, Kalvista, Pharming, Pharvaris, Takeda
Speaker- ARS, AstraZeneca, BioCryst, CSL Behring, Pharming, Grifols, GSK, Regeneron, Sanofi, Takeda, X4

Dana Wallace, MD - Speaker
Advisor- AbbVie, ARS, Bryn, Genentech, Kaleo

The following have no relevant financial relationships with ineligible companies to disclose:

Joseph Bellanti, MD - Planner, Speaker 
William Corrao, MD - Planner, Moderator 
Ginny Loiselle - Coordinator
Katelyn Loiselle, BSN, RN - Planner 
Emily McGowan, MD - Speaker 
Thomas Platts-Mills, MD - Speaker
Robert Settipane, MD - Planner, Moderator

Available Credit

  • 17.25 AMA PRA Category 1 Credit™
  • 17.25 Attendance
  • 17.25 CBRN
Please login or create an account to take this course.